Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 104 participants.
Also called NCT06657209
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 104 participants
- Sponsor
- Registry
-
NCT06657209
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06657209. Randomized; no masking; primary purpose treatment. Start 2025-01-13 (actual); primary completion 2027-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetes
- Condition
- Type 2 Diabetes
- Condition
- Pre Diabetes
- Intervention (Procedure)
- Insulin resistance testing
- Intervention (Procedure)
- OGTT
- Intervention (Procedure)
- Fat biopsy
- Intervention (Radiation)
- DXA scan
- Intervention (Procedure)
- MRI
- Intervention (Procedure)
- 1H-MRS
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Pioglitazone
- Lead sponsor
- Stanford University
Record details
- Record id
cardio:ct-nct06657209- Content hash
bd8981757c800adbeecaa17cec9e523056fc27bed3fee75e874fd28b0a541440